Race Oncology’s drug Zantrene shown to protect human heart muscle cells from anthracycline-induced chemotherapy death. Anthracycline’s are the most used.
Why the Race Oncology (ASX:RAC) share price is racing higher
Ken Hall | April 28, 2021 10:49am |
More on:
The
Race Oncology Ltd (ASX: RAC) share price is climbing today after an update from the Aussie healthcare company.
Why is the Race Oncology share price climbing?
Race Oncology announced that it has entered into a collaborative preclinical research program with The University of Newcastle. The purpose of the program is to investigate the heart safety Bisantrene offers over current anthracycline therapeutics.
Bisantrene is Race Oncology’s Phase 2/3 cancer drug that is a “potent inhibitor” of the Fatso/Fat mass and obesity-associated (FTO) protein. The possible role of FTO inhibition in Bisantrene’s lack of cardiotoxicity will be a primary focus of the new project.